Loading stock data…
CareDx (CDNA)
$37.14-0.47 (-1.25%)
Market ClosedLast close Jul 24
CareDx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CareDx, Inc. in the Healthcare sector is trading at $37.14 with a market capitalization of $1.3B. Wall Street consensus targets $35.40 (5 analysts), implying a -4.7% move over the next 12 months. The stock is currently near its 52-week high of $40.47, remaining 82.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $117.70M↑ | $108.39M↑ | $100.06M↑ | $86.68M↑ | $84.69M |
| Gross Profit | $84.07M↑ | $72.87M↑ | $69.40M↑ | $58.02M↑ | $56.27M |
| Operating Income | $1.80M↑ | -$6.04M↓ | -$246,000↑ | -$10.77M↓ | -$8.01M |
| Net Income | $2.81M↑ | -$4.11M↓ | $1.68M↑ | -$8.57M↑ | -$10.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney tra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.61%
Volume
Today's trading volume
464,378
Recent News
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage Limits - What's Changed
CareDx, Inc. previously announced that Medicare finalized a Local Coverage Determination for molecular testing to monitor solid organ transplant rejection, affirming coverage for its AlloSure Kidney, AlloMap and AlloSure Heart, and AlloSure Lung surveillance tests with defined testing limits over the first three years post-transplant. This decision removes a key reimbursement uncertainty for CareDx’s core transplant-testing portfolio, clarifying how frequently clinicians can use these...
CareDx (CDNA) Secures Medicare Reimbursement Clarity, Is The Upside Already Priced In?
CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ transplants, confirming reimbursement for the company’s kidney, heart, and lung transplant surveillance portfolio. See our latest analysis for CareDx. The finalized Medicare LCD arrives after a sharp swing in sentiment around CareDx, with a 30 day share price return of 69.21% and a 1 year total shareholder return of 233.45%, even though the 5 year total shareholder...
CareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage News
CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and recent share price strength point to a stock that may now be leaning expensive rather than clearly mispriced. Over the last three years, CareDx has returned 273.8%. This puts extra focus on whether the current price still reflects a reasonable balance between potential and risk. The finalization of Medicare coverage for CareDx’s solid organ transplant molecular tests...
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.